Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer

NCT06539091 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

51

Enrollment

OTHER_GOV

Sponsor class

Conditions

Epithelial Ovarian Cancer
Efficacy
Safety
Bone Mineral Density
Tolerability

Interventions

DRUG: Fluzoparib
DRUG: Apatinib Mesylate

Sponsor

Anhui Provincial Hospital